Onglyza Heart Failure Attorneys

If you or a loved one has taken Onglyza and suffered heart failure, you may have a legal claim against the manufacturer of Onglyza.

Request More Information

Based in the Philadelphia area, Pogust Braslow & Millrood is a plaintiffs’ law firm focused on fighting for the rights of patients harmed by dangerous drugs. We are currently investigating claims of heart failure caused by Onglyza (saxagliptin). A lawsuit can provide monetary damages for patients and their families to compensate for:

  • Hospitalization, medical treatment and ongoing care
  • Lost wages
  • Emotional distress caused by a loved one’s suffering
  • Funeral expenses.

Contact us today by calling 888-348-6787 or filling out our contact form and see what we can do for you.

The 2014 National Diabetes Statistics Report released by the American Diabetes Association reveals that almost 10 percent of the population had diabetes in 2012, and approximately 27.85 million of these cases have type 2 diabetes. Costs were estimated at $245 billion, and the prevalence of diabetes was projected to reach more than 592 million people worldwide by the year 2035.

Type 2 diabetes is a chronic disease characterized by insulin resistance and dysfunction of beta cells in the pancreas, leading to elevated glucose levels. When diet and exercise are not enough to manage diabetes, patients are prescribed medications to control blood glucose levels. These levels are affected by several organs and several different processes, so controlling them with medication can be a very complex process. There are numerous diabetes drugs on the market today, and each one has its own way of manipulating a specific organ or process. Some patients have to take more than one medication in order to get the desired effect.

Launched in 2009, Onglyza works to keep the hormone incretin from being broken down, stimulating insulin production and slowing digestion. Manufactured by AstraZeneca, the drug made $709 million in 2012, and analysts initially predicted that by 2018, annual sales of the drug could skyrocket to $2.47 billion. While common side effects were known to include respiratory tract infection, headache and urinary tract infection, a company-sponsored study of 16,000 patients showed that Onglyza might increase the risk of heart failure —a fatal condition in which the heart is unable to adequately pump blood to the heart, interrupting all biological functioning. Known as SAVOR, the study found that patients on Onglyza were 27 percent more likely to be hospitalized for heart failure, translating to an extra 0.6 percent of patients being hospitalized at 12 months.

Due to this increased risk of heart failure, a panel of advisors to the Food and Drug Administration (FDA) voted in April that the drug’s label should be updated to carry warnings of the risk. The FDA has not advised patients to stop using the drug, but this recent study may be cause for patients to reevaluate their drug regimen with their doctor. Furthermore, research has also shown a possible connection between Onglyza and chronic pancreatitis, which may lead to pancreatic cancer. Pancreatic cancer is one of the deadliest forms of cancer, and can be very difficult to diagnose in its early stages. As the potential link between Onglyza and cancer is being explored, cancer patients and their families may wish to consider their legal options.

It can be devastating to learn that a medication that was supposed to help someone actually ended up doing more harm than good. At Pogust Braslow & Millrood, we believe individuals who have suffered injury or the loss of a loved one due to Onglyza side effects have the right to pursue just compensation for their damages. We have a track record of successfully litigating against the manufacturers of dangerous drugs. If you or your loved one was harmed by Onglyza, let us seek justice for you. For a free consultation, contact us online or call 1-888-348-6787.